Find a Doctor
Jameel Muzaffar, MD
Specialty: Hematology/Oncology
Program: Head and Neck Oncology
Call 1-888-MOFFITT
(1-888-663-3488)
Call 1-888-MOFFITT
(1-888-663-3488)
Locations: Moffitt Cancer Center
Dr. Jameel Muzaffar is an Assistant Member in the Moffitt Cancer Center Department of Head and Neck-Endocrine Oncology. Dr. Muzaffar received his MBBS degree from Maulana Azad Medical College in India. He completed an Internal Medicine Residency at St. Mary’s Health Service in St. Louis, MO. Dr. Muzaffar was employed at the Myeloma Institute of Research and Therapy at the University of Arkansas for Medical Sciences at the rank of Assistant Professor. He also served as the Physician Director of Infusion 4, Winthrop Rockefeller Cancer Institute. Dr. Muzaffar was previously employed at Moffitt Cancer Center in the Department of Internal Medicine/Internal & Hospital Medicine Program. He recently completed a Clinical Fellowship in Hematology-Oncology at the University of Florida, Gainesville. Dr. Muzaffar’s clinical interest includes taking care of patients with advanced stage head and neck cancers and endocrine cancers. His clinical focus is developing a multi-disciplinary care approach involving radiation oncology, surgery, medical oncology, nutrition, speech pathology, pharmacy, palliative care, and social work to provide comprehensive care to head and neck cancer and thyroid cancer patients. His research interest is in developing new therapy options for patients with advanced stage cancers and to bring innovative trials for the benefit of these patients.
Education & Training
Board Certification:
- Internal Medicine
Fellowship:
- University of Florida at Gainesville - Hematology Oncology
Residency:
- Maulanza Asad Medical College - Internal Medicine
- St. Mary's Health Center - Internal Medicine
Medical School:
- Maulanza Asad Medical College - MBBS
CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230; Pembrolizumab (Keytruda)
Open
CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open
CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open
CLINICAL TRIAL 18994
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Condition: Head & Neck
Intervention: Radiotherapy; cisplatin
Open
CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open
CLINICAL TRIAL 19178
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Cetuximab; Erbitux (Cetuximab); Nivolumab
Open
CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open
CLINICAL TRIAL 18902
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: Avelumab; MSB00100718C (Avelumab); Placebo; Radiotherapy; cisplatin
Open
CLINICAL TRIAL 19442
Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer
Condition: Head & Neck
Intervention: BAY 43-9006 (Sorafenib); Cabozantinib (XL 184); E7080 (Lenvatinib); Lenvatinib (Lenvima); Sorafenib; Vandetanib
Open
CLINICAL TRIAL 19647
A Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients with Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: Cetuximab; Erbitux (Cetuximab); Ficlatuzumab
Open
If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.
- Nguyen TC, Bajwa R, Bari S, Ali A, Paul Skelton W, Federico RA, Bishnoi R, Wray JW, Zlotecki RA, Dang LH, Muzaffar J. Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. Oxf Med Case Reports. 2018 Jan;2018(1):omx078. Pubmedid: 29340160. Pmcid: PMC5761507.
- Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. Case Rep Hematol. 2018 Feb;2018:9052314. Pubmedid: 29785311. Pmcid: PMC5896379.
- Best J, Muzaffar J, Mitchell-Innes A. Quality of information available via the internet for patients with head and neck cancer: are we improving?. Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3499-3505. Pubmedid: 25370600.
- Hardman J, Muzaffar J, Nankivell P, Coulson C. Tympanoplasty for Chronic Tympanic Membrane Perforation in Children: Systematic Review and Meta-analysis. Otol Neurotol. 2015 Jun;36(5):796-804. Pubmedid: 25899552.
- Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D, Barlogie B, Usmani SZ. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):211-214. Pubmedid: 24373936.
- Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun;121(23):4753-4757. Pubmedid: 23603914. Pmcid: PMC3674673.
- Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol. 2013 Dec;130(3):146-149. Pubmedid: 23689541.
- Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):502-506. Pubmedid: 23747080.
- Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013 Aug;15(4):354-360. Pubmedid: 23578205.
- Abdallah AO, Westfall C, Brown H, Muzaffar J, Atrash S, Nair B. Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis. Am J Case Rep. 2013 Apr;13:102-105. Pubmedid: 23569501. Pmcid: PMC3615912.
- Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):171-174. Pubmedid: 23313066.
- Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012 Jan;95(1):102-106. Pubmedid: 22170228.
- Pillai U, Muzaffar J, Uppaluri C. Peripheral arterial thrombosis with presence of anti-centromere antibodies and polycythemia vera. Mo Med. 2009 Sep;106(5):369-372. Pubmedid: 19902720.
- Pillai U, Muzaffar J, Sen S, Yancey A. Grapefruit juice and verapamil: a toxic cocktail. South Med J. 2009 Mar;102(3):308-309. Pubmedid: 19204629.
- Singh P, Singla M, Gupta N, Muzaffar J, Babu R, Sakhuja P, Aggarwal A, Kar P. Inflammatory pseudotumour of the liver: a diagnostic dilemma. Trop Gastroenterol. 2008 Jan;29(1):40-43. Pubmedid: 18564668.
- Muzaffar J, Venkata Krishnan P, Gupta N, Kar P. Dengue encephalitis: why we need to identify this entity in a dengue-prone region. Singapore Med J. 2006 Nov;47(11):975-977. Pubmedid: 17075667.
- Gupta N, Krishnan PV, Muzaffar J, Arora A, Anuradha S, Gondal R, Agarwal A, Kar P. Cystic ductal adenocarcinoma of pancreas: an unusual variant. Trop Gastroenterol. 2006 Jul;27(3):131-133. Pubmedid: 17310557.
- Muzaffar J, Madan K, Sharma MP, Kar P. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Digest Dis Sci. 2006 Dec;51(12):2270-2273. Pubmedid: 17103040.
